Table 2 Antitumor responses according to FATSI staining
From: Pembrolizumab activity in patients with Fanconi anemia repair pathway competent and deficient tumors
Best Response | All (n = 41) | FATSI + (n = 29) | FATSI Neg. (n = 10) | (ND/In, n = 2) c |
|---|---|---|---|---|
CR | 2 | 0 | 2 | 0 |
PR | 5 | 2 | 3 | 0 |
SD | 11 | 9 | 2 | 0 |
PD | 21 | 17 | 3 | 1 |
NE | 2 | 1 | – | 1 |
iORR | 18% | 7% | 50% | 0% |
MiPFSa (range) | 47 (26-NR)b days | 43 (26-NR) days | 202 (41-NR) days | 39 (38–40) days |
20 Weeks PFS | 32% | 21% | 70% | 0% |